Key facts
- Lindis Blood Care’s last known valuation is $16.6M (Feb 2022).
- It has raised $5.4M; the latest was Later Stage VC ($1.6M) in Dec 2024.
- Notable investors include High-Tech Gründerfonds, Brandenburg Kapital, Bracht Beteiligungsgesellschaft, Investitionsbank des Landes Brandenburg.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Lindis Blood Care
- ·The full record, as it builds
Funding rounds
No funding rounds for Lindis Blood Care are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lindis Blood Care
Developer of a medical device designed to remove cancer cells from salvaged blood. The company's device allows the operation of tumors to open up the possibility of self-blood administration of blood collected during the operation, enabling cancer patients to benefit from the advantages of an autologous blood transfusion.
- Sector
- Healthcare
- HQ
- Hennigsdorf, Germany
- Founded
- 2018
- Employees
- 3
- Website
- lindis-bloodcare.com/
- Ownership
- Privately Held (backing)
Lindis Blood Care doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lindis Blood Care shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lindis Blood Care in its N-PORT filings yet. We sweep new filings monthly.